• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Buyouts

WCAS takes Abzena private for £34.4m

  • Kenny Wastell
  • Kenny Wastell
  • @kennywastell
  • 17 August 2018
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

US buyout house Welsh Carson Anderson & Stowe (WCAS) has received approval from shareholders at listed UK biotech and pharmaceutical company Abzena for a £34.4m take-private deal.

The proposed transaction values shares in the business at 16 pence apiece, equivalent to a 167% premium on the 6 pence closing price on 15 August and a 36% premium on the average closing price of 11.8 pence across the past three months.

In addition to the 1.7% stake accounted for by the Abzena board of directors, WCAS has received irrevocable undertakings from shareholders with a combined 76.3% stake in the company, surpassing the acceptance threshold of 75% set out in the offer document.

Abzena

  • DEAL:

    Buyout

  • VALUE:

    £34.4m

  • LOCATION:

    Cambridge

  • SECTOR:

    Pharmaceuticals

  • FOUNDED:

    2013

  • TURNOVER:

    £22m

  • EBITDA:

    -£12m

Abzena (formerly known as PolyTherics and Antitope) has a track record of venture backing and has previously received investment from Touchstone Innovations, Mercia Fund Management, Catapult Venture Managers, Beringea, YFM Equity Partners and Invesco Perpetual.

The two businesses merged in 2013 and listed the following year in a £20m IPO. The group has since expanded into the US by acquiring PacificGMP in San Diego and TCRS in Bristol, near Philadelphia. It raised a further £20m via a private placement in December 2015.

Technology- and healthcare-focused investor WCAS was recently reported to be targeting $3.75bn for its 13th fund, a considerable increase on the $3bn targeted for its predecessor vehicle.

Company
Abzena is headquartered in Cambridge and provides outsourced services to the biopharmaceutical industry, from the drug discovery stage through to the manufacturing phase. The company has additional laboratories and manufacturing sites in the US, and generated a turnover of £22m in the year ending in March 2018 with an adjusted EBITDA loss of £12m.

People
Welsh Carson Anderson & Stowe – Jonathan Goldman (operating partner); Brian Regan (general partner).
Abzena – Ken Cunningham (chairman); John Burt (CEO).

Advisers
Equity – Ropes & Gray (legal); Peel Hunt (corporate finance).
Company – Pinsent Masons (legal); N+1 (corporate finance).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • UK / Ireland
  • Healthcare
  • United Kingdom
  • Take Private
  • Ropes & Gray
  • Pinsent Masons

More on Buyouts

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
Ice cream
Exponent divests ‘significant' stake in Meadow to Canadian investor

Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy

  • Exits
  • 22 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013